ARTICLES

GEMMOTHERAPY VERSUS CONCENTRATED 
EMBRYONIC PLANT EXTRACTS

by Dr. Marie Gabrielle A. Laguna © 2015

Bilberry – Vaccinium Myrtillus (young shoots and fruits)

THE REAL STORY BEHIND THE 1DH DILUTION

Intolerance is the common misconception as to why Gemmotherapy 1DH dilutions became so wildly popular.  It is believed for there to be no intolerance, this type of gemmotherapy must be diluted. However, the truth of the matter is there is no “intolerance” issue.  In over 35 years of using concentrated extracts, there were only two cases of “intolerance”. Both were dermatitis cases due to intolerance of a particular compound, namely salicylates. When plants containing this phytochemical were removed, the intolerance was abated with no serious consequences.

Embryonic phytochemistry contains so many phytochemicals with natural anti-histamine properties (i.e. quercetin, astragaline, avicularin), making them free from allergic reactions. This is contrary to its counterpart adult phytotherapy which has many side effects and intolerance especially when used with an isolated and concentrated phytochemical approach.

Acceptance is the real reason for this 1DH dilution.  It could then be listed and qualified under the homeopathic pharmacopeia umbrella for reimbursement of homeopathic remedies and not because of intolerance.

Why would you want to dilute crucial phytochemicals and phytohormones which are already naturally diluted? In doing so, you ingest more alcohol from the 1DH dilution and obtain some benefits, but never as great as with the concentrated form.

WHY RENAME GEMMOTHERAPY TO EMBRYONIC PLANT EXTRACTS

Gemmotherapy from Latin word “gemma”, means bud, and “justo” which means therapy. The name Gemmotherapy is not appropriate since it only refers to “buds” and that this therapy we use many other parts of the plant beyond the exclusive use of buds. If this was the case the use of buds only, then it would make sense to call it Gemmotherapy. Medicinal Embryonic Phytotherapy (MEPTM) uses only fresh embryonic plant tissues in their infancy stage of growth: buds of leaves, buds of flowers, young shoots, embryonic fruits, embryonic roots, germinating seeds, and internal bark.

Embryonic concentrated plant extracts were first investigated in the late 1950s by a Belgian physician, Pol Henry MD (1918-88), he called it “Phytoembryotherapy” and began working with a group of French homeopaths and biotherapists including Max Tétau MD (1927-) and O.A. Julian MD. It was renamed “Gemmotherapy” by Max Tétau.

Pol Henry, our founder, never used the 1DH diluted form. The embryonic tissues contain all the genetic informative chemistry of the future adult plant in its developing stage of growth. They contain all of the potential biological activities and energy, which is the anabolic ability from embryonic plant extracts.

These embryonic plant extracts have very specific therapeutic targets at the cellular detoxification level and thereby regain normal organ function (homeostasis), and the regulation of apoptosis and other biological activities that are quite literally, too numerous to list them all. Reliable and dependable results can be achieved with embryonic plant extracts as a standalone Biotherapeutic program, and expected by the use of these embryonic plant extracts. Results will exceed those of adult phytotherapy due to the fact that adult phytotherapy produces inconsistent results.

In 1975 a French eclectic medical phytotherapist Dominique Richard, affiliated with Dolisos laboratories USA, was first to introduce this Biotherapy in the United States. Dominique Richard was trained in part by Dr. Max Tétau and, in time, was a mentor to him. He spent thirty five years researching embryonic phytotherapy documenting blood tests of individuals (before and after) to explain scientifically their biological therapeutic activities. He also identified many new phytohormones, phytochemicals and made many new discoveries and indications regarding their applications. His research is being published in the Medicinal Embryonic Phytotherapy Encyclopedia. It will be a text book of reference to designing a custom biotherapeutic program.  The book is due out in 2016.